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Abstract
Objective—This review evaluates costs and benefits associated with acquiring, implementing, 
and operating clinical decision support systems (CDSS) to prevent cardiovascular disease (CVD).
Materials and Methods—Methods developed for The Community Guide were used to review 
CDSS literature covering the period from January 1976 to October 2015. Twenty-one studies were 
identified for inclusion.
Results—It was difficult to draw a meaningful estimate for the cost of acquiring and operating 
CDSS to prevent CVD from the available studies (n=12) due to considerable heterogeneity. 
Several studies (n=11) indicated healthcare costs were averted by using CDSS but many were 
partial assessments that did not consider all components of healthcare. Four cost-benefit studies 
reached conflicting conclusions about the net benefit of CDSS based on incomplete assessments of 
costs and benefits. Three cost-utility studies indicated inconsistent conclusions regarding cost-
effectiveness based on a conservative $50,000 threshold.
Discussion—Intervention costs were not negligible but specific estimates were not derived 
because of the heterogeneity of implementation and reporting metrics. Expected economic benefits 
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from averted healthcare cost could not be determined with confidence because many studies did 
not fully account for all components of healthcare.
Conclusion—We were unable to conclude whether CDSS for CVD prevention is either cost-
beneficial or cost effective. Several evidence gaps are identified, most prominently the lack of 
information about major drivers of cost and benefit; the lack of standard metrics for the cost of 
CDSS; and not allowing for useful life of CDSS that generally extends beyond one accounting 
period.
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INTRODUCTION
The 2016 statistical update from the American Heart Association estimated that the annual 
cost of cardiovascular disease (CVD) and stroke in 2011–2012 was $193.1 billion in medical 
care and about $123 billion in lost productivity from premature death.(1) A substantial part 
of this burden is preventable by preventing and controlling major risk factors for CVD, 
including hypertension, hypercholesterolemia, and diabetes.(1) Clinical decision support 
systems (CDSS) are computer-based tools used to assist health providers to prevent and 
control these risk factors. The Community Preventive Services Task Force (Task Force) 
recently recommended CDSS for CVD prevention,(2) based on evidence from a systematic 
review conducted for The Community Guide.(3) The evidence showed CDSS improved 
screening for CVD risk factors and improved practices for CVD-related preventive care 
services, clinical tests, and treatments. The objective of the present study is to assess the 
economic value of CDSS interventions for CVD prevention, based on a systematic review of 
the literature.
METHODS AND MATERIALS
A full description of general methods for Community Guide systematic economic reviews is 
available online.(4). Briefly, Community Guide systematic economic reviews have the 
multiple objectives of providing evidence-based estimates of what it costs to implement an 
intervention, calculating the expected benefits from averted healthcare cost and worksite 
productivity losses due to reduced morbidity and mortality, and making a judgement of 
economic value based on estimated cost-benefit or cost-effectiveness. Estimates of economic 
outcomes generally vary considerably across evaluation studies. Therefore, Community 
Guide economic review methods attempt to account for the major elements that drive 
intervention costs and benefits, identified a priori based on information gained from 
published literature and subject matter experts.
Following the general methods, a systematic review team was constituted for the evaluation 
of CDSS for CVD prevention, including subject matter experts on CVD and CDSS from 
various agencies, organizations, and academic institutions together with expert systematic 
reviewers from The Community Guide branch at CDC. The team worked under the 
oversight of the Task Force.
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CDSS for CVD prevention were defined as computer-based information systems designed to 
assist healthcare providers, in primary, secondary, and tertiary care settings, implement 
guidelines and evidence-based practices by providing tailored reminders to conduct or 
schedule preventive and screening services; assessments of patients’ risk for developing 
CVD based on their medical history; and alerts when CVD-related physiologic indicators 
are not at goal. The CDSS interface with the provider occurs at the point of care, based on 
individual patient data, and assists providers with recommendations for screening, 
preventive care, and treatment of their patients who have risk factors for CVD such as 
obesity, inactivity, smoking, hypertension, hyperlipidemia, or diabetes. Improved clinician 
actions should mitigate these risk factors and ultimately lead to reduced morbidity and 
mortality from CVD and therefore also improve economic outcomes. The complete 
definition and analytic framework are available in the published review of effectiveness.(3)
Search strategy and inclusion criteria
The studies for this systematic economic review were drawn from the results of three 
searches:
1. The primary source was the set of studies referenced in a broad systematic 
review published in 2012, Bright et al.,(5) and the in the accompanying report to 
the Agency for Healthcare Research and Quality (AHRQ).(6)
• Period: January 1975–January 2011
• Databases: PubMed, CINAHL, PsycINFO, PubMed NLM, and Web of 
Science
• Scope: CDSS in all health topics
2. The Bright et al. search was updated to cover more recent studies
• Period: January 2011–October 2015
• Databases: PubMed, CINAHL, PsycINFO, PubMed NLM, and Web of 
Science
• Scope: CDSS in CVD prevention
3. Search was conducted within economics-related databases using the strategy 
implemented in Bright et al.
• Period: January 1970–October 2015
• Databases: JSTOR, EconLit, Centre for Reviews and Dissemination
• Scope: CDSS in CVD prevention
The three searches used terms to identify evaluation studies of CDSS to prevent CVD across 
healthcare settings and ages. The studies referenced in the Bright et al. review were further 
screened to identify those related to CVD prevention because that review considered CDSS 
use under all health topics. Details including the complete list of search terms for the 
domains of CDSS intervention, target population, CVD prevention, and the databases 
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searched for the Bright et al. search and its update are available online,(7) as are similar 
details for the economics-focused search.(8)
Studies were included in this review if they:
• met the intervention definition;
• were in English;
• were implemented in a high-income economy;(9) and
• reported one or more of: the cost of intervention, change in healthcare cost, 
change in productivity, other economic benefits, cost-benefit, or cost-
effectiveness.
CDSS interventions are generally implemented in clinics, hospitals, and other healthcare 
settings and the cost of implementation is borne by the same organizations. However, 
benefits can accrue to patients, their employers, or insurers. This review took both a health 
system and a societal perspective when assessing cost and benefit, so that reported estimates 
are meaningful for both the public and commercial perspectives of these implementers and 
funders.
Intervention cost—The cost to develop the CDSS is the cost of compiling evidence-based 
narrative guidelines and programming the guidelines and decisions into code to produce 
prompts for provider action. Resources are needed to then implement the system throughout 
the practice and for all providers. The day-to-day use and maintenance of the CDSS require 
staff time and other resources, and are categorized under operating cost. In summary, the 
components of capital cost are development and implementation and the components of 
operating cost are maintenance and operation. Annualized intervention cost was estimated 
by distributing the one-time cost of development and implementation equally over the 
assumed 5-year life of the system and adding this annual amortized cost, discounted at 3%, 
to the annual cost of operation. Details regarding the conceptualization and measurement of 
intervention cost is presented in the Appendix 1.
A CDSS may be embedded within an electronic health record (EHR) system containing 
patient demographics and all health-related data or it may be built on a registry that contains 
information only for patients with a specific disease or condition. The cost of collecting and 
populating the database with patient information, whether for an EHR or a registry, is not 
considered part of CDSS intervention cost.
A CDSS may also change the economic efficiency of the care process by altering the 
resources needed to care for a patient or by altering the number of patients cared for with the 
same level of resource use. The benefits of this efficiency accrue to the healthcare facility 
implementing the CDSS and would be observed in operation cost per patient or per patient 
visit.
Intervention economic benefits—Effective CDSS interventions reduce CVD risk 
factors, such as systolic blood pressure. The reduction in risk factors, in turn, reduces 
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morbidity and mortality and increases the quantity and quality of years lived, measured as 
quality-adjusted life years (QALYs) saved.
The impact of CDSS on healthcare cost is the difference in cost of healthcare products and 
services used by the intervention and control groups or the pre to post change where there is 
no control group. The implementation of CDSS in health care can increase or decrease 
healthcare utilization by the patient, either owing to adherence to guidelines for care 
(increased cost) or to improved health (decreased cost). The sum of these two changes is 
observed in changes in the component cost of outpatient, inpatient, medications, labs, and 
emergency room (ER) visits. A full accounting of healthcare cost would include all five of 
these components; this review considers them to be of equal weight and an estimate that 
includes at least three of the five components to be reasonably complete.
Reduced illness and increased years of life lived contribute to fewer illness-related absences 
from work, better performance when present, and a longer period of productivity. Hence, 
effective CDSS implementations that prevent CVD are expected to increase worksite 
productivity.
Reduced morbidity and mortality also increase both the quantity and quality of life years 
lived. This is captured in outcomes such as QALYs saved or disability-adjusted life years 
(DALYs) averted.
Summary economic outcomes—Cost-benefit analysis compares economic benefit to 
intervention cost, where both benefit and cost are monetized and expressed in dollar terms; 
an intervention is cost-beneficial when economic benefit exceeds intervention cost.
Net cost (intervention cost plus healthcare cost) per QALY gained produces cost-utility, 
which is a type of cost-effectiveness assessment. An intervention is cost-effective when net 
cost per QALY gained is less than a $50,000. A threshold is applied because it is necessary 
to determine cost-effectiveness(10) and $50,000 is chosen for the threshold because it is a 
conservative estimate and the one most widely used in the literature.(11)
Measurements, metrics, and reviewer decisions
Intervention cost can differ for practices of different sizes because the scale of CDSS 
implementation ranges from small clinics to large health centers. The review team decided 
that intervention cost should be characterized by the size of practices where the CDSS is 
implemented. However, this review did not find any studies that fully characterized the 
association between cost of CDSS implementation and size of practice, whether based on 
number of physicians or of patients in the practice. Therefore, we used the following 
categories of practice size (based on number of physicians) reported in the 2012 survey of 
practices by the American Medical Association (AMA)(12) to classify practices: Small, 1–4 
physicians (40% of respondents); Medium, 5–24 physicians (35% of respondents); Large, 
≥25 physicians (25% of respondents). For studies that reported only the number of patients, 
we estimated the number of physicians, based on an average patient panel and workload of 
U.S. primary care physicians.(13). All other cost and economic benefit estimates from 
included studies were standardized to a per-patient per-year basis when possible.
Jacob et al. Page 5













All monetary values were converted to 2015 U.S. dollars. The Consumer Price Index from 
the Bureau of Labor Statistics(14) was used to adjust for inflation. Purchasing Power Parity 
indices from the World Bank were used to convert from foreign currencies to U.S. dollars.
(15) Results are summarized using medians and interquartile intervals.
RESULTS
Twenty-one studies from the 7,508 papers screened met inclusion criteria (Figure 1). 
Seventeen studies(16–28) reported on EHR- or electronic medical record (EMR)-based 
CDSS, one study(29) piloted a CDSS residing on a stand-alone desktop, one(30) was based 
on a diabetes registry, and two studies(31–33) covered both EHR-based and registry-based 
CDSS (two papers(32, 33) reported on the same research and are counted as one study for 
this review). Table 1 provides an overview of additional characteristics of the included 21 
studies. Most of the studies were based in the U.S. (67%) and implemented in clinics (94%), 
based on trials with a control group (63%) or models based on trials (25%). The studies 
covered CDSS implemented alone (36%) or in combination with patient reminders/
education (18%), or with team-based care (23%), where primary care providers and patients 
worked together with other providers to improve care and self-management support for 
patients. Most studies focused on diabetes (47%) as a risk factor, followed by other CVD 
risks. More than 90% of the studies were published since 2000. Details of the included 
studies are available online.(34)
Intervention Cost
Twelve studies reported estimates of intervention cost which are presented in Table 2 for 
registry- and EHR-based CDSS implementations. The estimates are characterized further by 
size of the healthcare practice and whether studies included cost of development and 
implementation, ongoing cost of operations, or both. Nine(18, 21–23, 25, 27, 30–33) of the 
12 studies reported the intervention cost of CDSS implementations specifically (Table 2). Of 
the remaining three studies, two studies that provided the cost of intervention did not include 
the cost of CDSS, with one(35) reporting the cost of adding provider incentives to the CDSS 
implementation and the second(36) providing only the labor cost of the staff involved in 
team-based care. The intervention cost from another study(29) was computed by the review 
team from the incremental cost per unit reduction in low density lipoprotein-c (LDL-C) 
reported in the study, and is therefore assumed to include change in healthcare cost of 
outpatient visits and medications.
All three studies that assessed the cost of CDSS implemented in diabetes registries included 
both the one-time capital cost and ongoing operations cost. Based on a survey of users and 
vendors, one(31) of the studies estimated the annual cost per practice for a registry-based 
CDSS was about $9,500 for a small, $20,600 for a medium, and $76,000 for a large practice. 
The corresponding estimates for cost per patient per year were $69, $23, and $14, 
respectively. A U.S. study(32, 33) that modeled the cost of scaling up a registry-based CDSS 
nationwide estimated the annual per patient costs at $55, which corresponds closely with the 
survey-based estimate for a small practice. On the other hand, another U.S. study(30) 
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estimated the annual cost of a medium-size CDSS at $106 per patient ($132,400 per 
practice), based on data collected during a controlled trial.
Eight studies reported the intervention cost of EHR-embedded CDSS, of which five(18, 22, 
23, 31–33) included both cost of development and implementation and ongoing cost of 
operation and three(21, 25, 27) included only the one-time cost of development and 
implementation. Among the five studies that provided reasonably complete assessments of 
intervention cost, the mean annual costs were: $102 per patient(18, 23, 32, 33) and $6,056 
per practice(18, 23) for small practices, and $49 per patient and $35,201 per practice(22, 31) 
for medium-sized practices.
Change in Healthcare Cost
Change in healthcare cost attributable to the intervention was reported in 15 studies: 13(16–
25, 28, 37, 38) EHR-based implementations, one(30) registry-based, and one(32, 33) 
reporting both types (Table 3). Interventions in addition to the CDSS were present in several 
studies; therefore, the effect on healthcare cost and other outcomes cannot be attributed to 
CDSS alone. This is especially the case where intensive interventions were added, as for 
four CDSS interventions that included team-based care,(18, 24, 28, 38) followed by those 
that added less-intensive interventions, such as quality improvement,(37) provider 
incentives,(22) provider audit and feedback,(21) and patient reminders.(20, 32, 33)
Based on eight studies(16–19, 22, 24, 25, 30) that included at least three of five components 
of healthcare cost, the median change in healthcare cost per patient per year was −$35 
(interquartile interval [IQI]: −$127 to $75). However, the estimated change in healthcare 
cost cannot be attributed to CDSS alone for two(18, 24) nterventions that included team-
based care. With these studies removed, the remaining 6 studies produced a median change 
in healthcare cost per patient per year of −$35 (IQI: −$114 to $93).
Worksite Productivity
No studies assessed the economic benefit of worksite productivity improvements for patients 
whose health improved through use of a CDSS.
Cost-benefit and Cost-effectiveness
Economic benefit was compared to intervention cost in two(21, 23) studies of EHR-based 
CDSS and one(32, 33) study of both EHR- and registry-based CDSS (Table 4). The same 
time horizons were used for benefits and cost in these studies. All three studies included 
fewer than three components of healthcare cost and did not estimate productivity effects; 
they were therefore incomplete assessments of economic benefit. One study(21) that 
reported a benefit-to-cost ratio of 2.03:1 considered only the averted cost of medication and 
did not include ongoing operating cost in its estimate for intervention cost. The second 
study(23) provided a reasonably complete assessment of intervention cost but only 
considered the cost of inpatient stays and emergency room (ER) visits, estimating benefit-to-
cost at 3.8:1. The third study(32, 33) estimated the benefit of averted inpatient stays and 
outpatient visits to a reasonably complete assessment of intervention cost at 2.3:1 for a 
registry-based CDSS but 0.55:1 for an EHR-based CDSS. The latter, unfavorable, ratio arose 
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primarily because the only high-quality trial of an EHR-based CDSS for diabetes 
management at the time showed an increase in systolic blood pressure for the intervention 
group, which translated to increased CVD risk and CVD events in the economic modeling. 
In summary, the results from cost-benefit studies are incomplete assessments and indicate 
mixed conclusions on whether economic benefits exceed the cost of CDSS interventions to 
prevent CVD.
Three studies provided estimates of cost per QALY saved (Table 4), where the same time 
horizons were used for net cost and adjusted life years lived outcomes: two reported the 
interventions were cost-effective at $49,000(18) and $16,500(22) and one reported that it 
was not cost-effective at $143,000.(25) Estimates for healthcare cost from all three studies 
were reasonably complete but one study(25) did not include annual operating cost in the 
intervention cost. Further, the two studies with cost per QALY saved <$50,000 included 
interventions in addition to CDSS, namely team-based care(18) and provider incentives.(22) 
The demonstration of cost-effectiveness from these two studies is for the combination 
intervention and cannot be attributed to CDSS alone.
DISCUSSION
A recent symposium concluded(39) that methodologies are yet to be developed that can 
rigorously evaluate the economic value of health information technologies at the population 
and national level even though economic value is evident from individual observations of 
their success at the local and organizational level. The symposium noted the difficulty in 
transitioning from judgements of economic value at the level of specific implementations to 
a judgement about the aggregate of the implementations: costs and benefits have to be 
summed over implementations with different organizational contexts, technologies, 
functions, outcomes, scales, and scope. This systematic economic review of one type of 
health information technology, namely CDSS, encountered similar difficulties among others 
in synthesizing the economic evidence from various implementation instances.
The cost and economic benefit of CDSS implementations from included studies were poorly 
reported and many studies did not adhere to sound evaluation or accounting practices. Only 
a few studies provided a complete accounting of cost to develop, implement, maintain, and 
operate a CDSS. More complete economic evaluations are necessary to obtain reliable 
estimates for intervention cost across types and sizes of healthcare settings. Reported 
economic benefits of a CDSS are often determined or guided by the implementation’s 
disease or risk-factor focus (e.g., hypertension, CVD, diabetes, depression), functionality 
(e.g., provider prompts, management of orders, disease management), or the implementer’s 
objective (e.g., containing cost with cheaper drugs or averting hospital re-admissions). 
However, despite the heterogeneity in the research literature for the focus, functionality, and 
objective of CDSS implementations, certain guidelines for the evaluation of economic costs 
and benefits can still be described.
Starting with cost, important features of CDSS from an evaluation perspective are its useful 
life that generally spans multiple years, and the substantial one-time cost of development 
and implementation. In addition to the one-time cost, maintaining and operating the CDSS 
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requires technical and medical staff time. The present review estimated intervention cost as 
the sum of these two components, based on recommended accounting practices and tax 
rules. Details and references are provided in Appendix 1. Because the cost of a CDSS is 
generally borne by the practice and may differ by practice size, it is useful to communicate 
the intervention cost in both per-practice and per-patient terms. Most included evaluation 
studies did one or the other. An additional advantage of intervention cost measured in per-
patient terms is its immediate comparability to healthcare cost and health effects that are 
generally reported in per-patient terms.
Moving to the benefits side of the evaluation, only those benefits that likely resulted from 
changes in provider clinical decisions and any consequent change in patient behavior and 
health should be ascribed to the CDSS implementation. The societal perspective is 
recommended for economic evaluations to account for all healthcare, regardless of who pays 
for the various components. It is important to know what impact the CDSS has on total 
healthcare utilization; following the guidelines prompted by the CDSS may increase 
outpatient visits and/or medications within primary care but may avert very costly inpatient 
stays and ER visits in tertiary care. This is not to say a partial perspective is without merit. A 
primary care study evaluating a CDSS to treat hypertension may report the intervention cost 
per unit reduction in blood pressure ($/mmHg), a useful statistic for clinic managers.
Evaluations are more complex when one or more additional interventions occur along with 
the CDSS. Both the intervention cost and economic benefit (including QALY saved) must be 
ascribable to the CDSS when statements are made about the cost-benefit or cost-
effectiveness of CDSS implementations. It is often feasible to estimate the cost of the CDSS 
and additional intervention(s) separately, but obtaining separate estimates for benefits from 
the component intervention(s) is likely to be difficult, whether analytically or by study 
design. For example, in an intervention where team-based care is implemented along with 
the CDSS, a cost-benefit analysis that included only the cost of CDSS in intervention cost 
and the combined effect of both team-based care and the CDSS in the benefits would be 
incomplete. In the absence of complete data, statements about the economic value of the 
CDSS would have to include appropriate caveats.
Many studies included in this review focused on a single CVD risk factor such as diabetes, 
high cholesterol, or high blood pressure. Outcomes for lifetime cost per QALY saved or 
cost-benefit ratios were often modeled based on measured improvements in a single or a few 
risk factors such as blood pressure, blood glucose, or cholesterol. However, a CDSS for 
CVD prevention and control would, in practice, be implemented with a multiplicity of 
functionalities including simple provider and patient reminders for screening and testing, 
patient risk assessments, and medication and lifestyle counseling recommendations across 
the range of risk factors and indicators for CVD (and diabetes).
The results presented in the current review are consistent with those found in the broader 
review of evidence for CDSS implementations for all diseases and conditions.(5, 6) That 
review found that CDSS/Knowledge Management Systems reduced healthcare cost and 
produced healthcare cost-savings, but it reached mixed conclusions about cost-effectiveness. 
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Similar to the current review, that review also called for evaluations to standardize the 
metrics for efficiency and cost.
CONCLUSION
An overall conclusion cannot be reached about the cost-effectiveness or cost-benefit of 
CDSS for CVD prevention and control. The evidence on cost and benefit is limited by many 
estimates that do not account for major components, and mixed evidence when the estimates 
are reasonably complete. Further, the reported cost and benefit in many studies included the 
effect of interventions in addition to the CDSS.
The quality of economic evidence for CDSS can improve with more evaluations that 
acknowledge its capital good features and account for both development and operating cost 
over its span of useful life.
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Table 1
Characteristics of Included Studies and Proportion of Studies with Each Characteristic
Characteristic No. of studies(% of all reviewed studies)
Country U.S. 14 (16, 20, 22–24, 26–28, 30–33, 35–37)
(67%)
Non-U.S. 7 (17–19, 21, 25, 29, 38)
(33%)
Setting Clinic 18 (16–25, 27–33, 35, 37)
(86%)
Hospital 3 (26, 36, 38)
(14%)
Study Type Trial 15 (16, 17, 19, 20, 23, 24, 26–30, 35–38)
(71%)
Model 1 (32, 33)
(5%)








Hyperlipidemia 2 (17, 19)
(10%)
Hypertension and Hyperlipidemia 1 (21)
(5%)
Including multiple CVD risk factors 7 (16, 20, 23, 26, 27, 29, 35)
(33%)
Control group Pre and post with no control group 5 (17, 27, 36–38)
(24%)
With control group 14 (16, 18–26, 28–30, 35)
(67%)
Survey, Model with no control group 2 (31–33)
(10%)
Intervention added to CDSS Team-based care 5 (18, 24, 28, 36, 38)
(23%)
Provider incentives 2 (22, 35)
(9%)
Provider audit and feedback 1 (21)
(5%)
Patient phone reminders or report to patient 4 (20, 23, 31–33)
(18%)
Quality improvement 2 (35, 37)
(9%)
None 8 (16, 17, 19, 25–27, 29, 30)
(36%)
Publication period 1990s 2 (20, 26)
(9%)
2000s 9 (16, 17, 19, 21, 24, 28, 30–33)
(43%)
2010s 10 (18, 22, 23, 25, 27, 29, 35–38)
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Characteristic No. of studies(% of all reviewed studies)
(48%)
CDSS, clinical decision support system; CVD, cardiovascular disease


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Jacob et al. Page 18
Table 4
Cost-Benefit and Cost per QALY Saved Estimates
Study Type of CDSS Benefit-to-Cost Ratio
Fretheim 06b (21)
EHR -based
0.42:1 over 12 months




Bu 07a,b (32, 33)
EHR -based
0.55:1
Bu 07a,b (32, 33)
Registry-based
2.3:1
Cost per QALY saved
Cleveringa 10 (18)
EHR-based
All patients − $49,500
Patients with CVD − $19,600







CDSS, clinical decision support system; CVD, cardiovascular disease; EHR, electronic health record; QALY, quality-adjusted life year;
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